Janssen submits hepatitis C drug candidate Simeprevir for FDA approval

04/2/2013 | Pharmaceutical Business Review Online

Janssen Research & Development filed a new drug application with the FDA for approval to use its NS3/4A protease inhibitor Simeprevir, or TMC435, with pegylated interferon and ribavirin as a treatment for genotype 1 chronic hepatitis C. The application was based on results of late-stage trials involving previously untreated and treatment-experienced patients with compensated liver disease.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ